التفاصيل البيبلوغرافية
| العنوان: |
Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review. |
| المؤلفون: |
Bergsbaken, J. J., Eickhoff, J. C., Buss, B. A., Mably, M. S., Kolesar, J. M. |
| المصدر: |
Journal of Oncology Pharmacy Practice; Feb2016, Vol. 22 Issue 1, p105-113, 9p, 1 Diagram, 4 Charts, 1 Graph |
| مصطلحات موضوعية: |
ANTINEOPLASTIC agents, DRUGS, EXPERIMENTAL design, INTERNAL medicine, MEDICAL protocols, MEDLINE, MOUTH tumors, ONLINE information services, PATIENT compliance, QUALITATIVE research, DATA analysis software, DESCRIPTIVE statistics |
| مستخلص: |
Background Despite recommendations for adherence reporting in clinical trials involving an oral anticancer agent, the frequency and methods of adherence reporting are inconsistent. The purpose of this systematic review is to determine the frequency and type of adherence measures used in oncology and hematology clinical trials of oral anticancer agents and their association with study characteristics including quality, cancer type, stage and treatment type. Design PubMed was searched of all randomized controlled clinical trials assessing self-administered pharmacological interventions in patients with cancer and published over two years, between 1 January 2011 and 31 December 2012 were evaluated. Results We identified 70 publications in the PubMed database, comprising 45,118 total patients. Adherence reporting was present in 14 of 70 trials (20%); quantitative reporting was present in three of 70 trials (4%). Method of adherence assessment varied and included medication count, medication diaries and patient self-report. There was no association between adherence reporting and study quality or other study characteristics, although there was a trend towards increased reporting in breast cancer studies, with 46% of the studies reporting adherence (p = 0.0621). In a preliminary analysis, hematology studies (mean Jadad score 2.19 ± 1.47) were found to have significantly lower quality when compared to non-hematology trials (mean Jadad score 3.39 ± 1.37, p = 0.0034). Conclusion This systematic review demonstrates adherence reporting in clinical trials of oral anticancer agents is infrequent. When reported, adherence was not associated with overall study quality or other study characteristics. Given the potential effects of non-adherence on study power and validity, adherence reporting should be encouraged in oncology and hematology clinical trials. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Oncology Pharmacy Practice is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
